As a world leader of in vitro diagnostics, QuidelOrtho offers industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic.
Company profile
Nasdaq: QDEL
Footprint: 130+ Countries
2024 Revenue: $2.8B
QuidelOrtho is a responsive, reliable partner to the U.S. government
In March 2020, shortly after the first COVID-19 patient was diagnosed in the U.S., QuidelOrtho’s President & Chief Executive Officer was invited to meet with the newly formed White House Coronavirus Task Force to discuss testing. Two weeks later, the company began shipping its first emergency-use-authorized Lyra® test for COVID-19. In May 2020, QuidelOrtho introduced a test compatible with the Sofia® and Sofia® 2 analyzers – the first-ever 15-minute rapid antigen test to detect COVID-19.
QuidelOrtho is committed to meeting the needs of the U.S. government
In just two years, the company partnered with the National Institutes of Health’s Acceleration of Diagnostics to expand Sofia test manufacturing from 84 million test cassettes per year to more than 220 million cassettes per year. In 2021, the company received emergency use authorization (EUA) for its QuickVue® At-Home OTC COVID-19 Test and quickly opened a 128,000-square-foot facility with the capacity to manufacture the COVID-19 tests that tens of millions of Americans relied on during the pandemic.
QuidelOrtho believes in the value of public-private partnerships
QuidelOrtho works closely with the U.S. Department of Health and Human Services and the Department of Defense to help the government’s efforts to provide tests to Federally Qualified Health Centers, government agencies and American families.
Case studies
Challenge:
In March 2020, as COVID-19 began spreading rapidly across the U.S. and around the world, the U.S. government recognized that diagnostic tests, vaccines and therapeutics were going to be essential to protecting public health. From a testing standpoint, the U.S. government requested rapid development of an antigen test for mass distribution across the country. The test needed to be accurate, convenient, accessible and cost-effective, enabling individuals to test themselves easily and quickly at home.
Solution
In response to this urgent need, QuidelOrtho developed, tested, validated and received its first EUA for the Lyra® COVID-19 test.
Outcome
Over the course of the pandemic, working in partnership with the U.S. government, QuidelOrtho has provided tens of millions of accurate, reliable and affordable tests to the public and donated tests to underserved communities where access to testing was difficult.
Conclusion
QuidelOrtho is proud of its role in partnering with the U.S. government to protect public health throughout the pandemic.
U.S. employees by region
*Approximate number of U.S.-only employees as of May 2023.
Our offerings
Customer Experience Program
Labs
Molecular Diagnostics
Point of Care
Transfusion Medicine
QuidelOrtho understands and values the role small businesses play in our communities. Today, the company does business with more than 600 small businesses across the U.S., including several that are U.S. government–certified small and disadvantaged companies.
Certified Small and Disadvantaged Business Partners
- Cenmed Enterprises
- Hazlow Electronics Inc
- Keystone Environmental
- Pacific Technologies and Solutions
- Tirone Electric Inc
- United Seal and Rubber Co Inc
With more than 300 diagnostic test products available around the world, QuidelOrtho invests heavily in research and development. The company has research relationships with a growing number of universities and colleges.
Learn more about QuidelOrtho’s relationships with the U.S. government or colleges/universities.
